NEW CEO OF TEVA IS DETERMINED TO ACT DECISIVELY
Detailed plan for reorganization will be unveiled shortly and five new TOP-managements are to come into TEVA governance.
Kare Shultz, New Chief Executive Officer of Israel–based pharmaceutical company TEVA has made a decision to fire several TOP-managers of the Company and also to combine a number of departments, informs Remedium with reference to FiercePharma.
Within the framework of business optimization Mr. Shultz intends to combine the manufacturing of generic and specialty drugs into one business unit, R&D departments of these units are also to be emerged. Detailed plan for reorganization will be unveiled shortly.
As the result of personnel reshufflings Dr. Rob Koremans, president and CEO, global specialty medicines; Dipankar Bhattacharjee, president and CEO, global generic medicines group and Dr. Michael Hayden, president of global R&D and chief scientific officer - will retire from Teva. Five new TOP-managements will join TEVA management team.
TEVA Ukraine is a part of Teva Pharmaceuticals, the leading international pharmaceutical corporation specializing in the development, production and marketing of generic and proprietary-branded pharmaceuticals.